GLAXOSMITHKLINE PLC
GSK
 Delayed - 04/15 11:35:28 am |
|
| 1348.4GBX | +4.56% |
Business Summary
| Healthcare | ||||
 | Pharmaceuticals & Medical Research | |||
| Pharmaceuticals | |||
| Pharmaceuticals | |||
| Other Pharmaceuticals | |||
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows:
- pharmaceutical products (50%): intended for respiratory diseases (64.9% of net sales), HIV infection (28.6%), immune system disorders (4.3%) ) and cancer (2.2%);
- OTC and parapharmaceutical medicine (29.4%);
- vaccines (20.5%);
- other (0.1%).
Net sales are distributed geographically as follows: the United Kingdom (2.9%), the United States (42.7%) and other (54.4%).
Number of employees : 94 066 people.
- pharmaceutical products (50%): intended for respiratory diseases (64.9% of net sales), HIV infection (28.6%), immune system disorders (4.3%) ) and cancer (2.2%);
- OTC and parapharmaceutical medicine (29.4%);
- vaccines (20.5%);
- other (0.1%).
Net sales are distributed geographically as follows: the United Kingdom (2.9%), the United States (42.7%) and other (54.4%).
Number of employees : 94 066 people.
Sales per Business
| 2019 | 2020 | |||
| GBP (in Million) | % | GBP (in Million) | % | |
| Pharmaceuticals | 17,554 | 52% | 17,056 | 50% |
| Consumer Healthcare | 8,995 | 26.6% | 10,033 | 29.4% |
| Vaccines | 7,157 | 21.2% | 6,982 | 20.5% |
| Corporate and Other Unallocated | 48.00 | 0.1% | 28.00 | 0.1% |
Sales per region
| 2019 | 2020 | |||
| GBP (in Million) | % | GBP (in Million) | % | |
| United States | 13,890 | 41.2% | 14,556 | 42.7% |
| Rest of World | 11,795 | 34.9% | 11,379 | 33.4% |
| Europe | 7,127 | 21.1% | 7,184 | 21.1% |
| United Kingdom | 942.00 | 2.8% | 980.00 | 2.9% |
Managers
| Name | Title |
| Emma N. Walmsley | Chief Executive Officer & Executive Director |
| Iain James Mackay | Chief Financial Officer & Executive Director |
| Jonathan Richard Symonds | Non-Executive Chairman |
| Karenann K. Terrell | Chief Digital & Technology Officer |
| Hal V. Barron | Executive Director & Chief Scientific Officer |
| Jon Ellis | VP & Head-Technology Business Development |
| Amy Altshul | SVP-Legal, Research & Development |
| Nick Hirons | Senior Vice President-Global Ethics & Compliance |
| Judy Carol Lewent | Independent Non-Executive Director |
| Lynn Laverty Elsenhans | Independent Non-Executive Director |
| Shareholders |
| Name | Equities | % |
| The Vanguard Group, Inc. | 138,925,000 | 2.76% |
| BlackRock Fund Advisors | 131,211,690 | 2.61% |
| BlackRock Investment Management (UK) Ltd. | 128,982,522 | 2.56% |
| Norges Bank Investment Management | 125,399,000 | 2.49% |
| Capital Research & Management Co. (Global Investors) | 108,509,979 | 2.16% |
| Dodge & Cox | 99,377,874 | 1.98% |
| State Street Global Advisors Ltd. | 66,661,377 | 1.33% |
| BlackRock Advisors (UK) Ltd. | 65,153,969 | 1.30% |
| Schroder Investment Management Ltd. | 63,637,317 | 1.26% |
| Capital Research & Management Co. (World Investors) | 61,076,263 | 1.21% |
Company contact information
980 Great West Road
TW8 9GS Brentford, Greater London
Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com
TW8 9GS Brentford, Greater London
Phone : +44 (0)20 8047 5000
Fax : +44 (0)20 8047 7807
web site : http://www.gsk.com
Markets and indexes
| - |
| - Main Market |
| - FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50 |
Stock Exchange Codes
| - Bloomberg Code : | GSK:LN |
| - Reuters Code : | GSK.L |
| - Datastream Code : | GSK |
Sector Other Pharmaceuticals
| 1st jan. | Capi. (M$) | ||
 | |||
| GLAXOSMITHKLINE PLC | 2.37% | 88 637 | |
| |||
| JOHNSON & JOHNSON | 1.61% | 421 022 | |
| ROCHE HOLDING AG | -0.02% | 288 425 | |
| PFIZER INC. | 0.95% | 207 340 | |
| NOVARTIS AG | -4.51% | 195 369 | |
| MERCK & CO., INC. | -6.60% | 193 391 | |
| ABBVIE INC. | -1.17% | 186 895 | |
| ELI LILLY AND COMPANY | 8.39% | 166 346 | |
| NOVO NORDISK A/S | 2.82% | 162 882 | |
| AMGEN INC. | 8.71% | 143 732 | |
| BRISTOL-MYERS SQUIBB COMPANY | 2.50% | 142 547 | |
| ASTRAZENECA PLC | -0.72% | 131 672 | |
| SANOFI | 6.73% | 125 614 | |
| GLAXOSMITHKLINE PLC | -3.90% | 88 637 | |
| JIANGSU HENGRUI MEDICINE CO., LTD. | -26.27% | 69 532 | |
| CHUGAI PHARMACEUTICAL CO., LTD. | -22.28% | 64 689 | |
| ALLERGAN PLC | 0.97% | 63 659 | |
| BAYER AG | 9.85% | 62 225 | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | -1.07% | 53 139 | |
| DAIICHI SANKYO COMPANY, LIMITED | -14.71% | 52 365 | |
| ASTELLAS PHARMA INC. | 3.73% | 28 058 | |
Brand Portfolio
